Jump to ContentJump to Main Navigation
Show Summary Details

Buchner, Johannes

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Lei, Ming / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

SCImago Journal Rank (SJR) 2015: 1.607
Source Normalized Impact per Paper (SNIP) 2015: 0.751
Impact per Publication (IPP) 2015: 2.609

See all formats and pricing



Select Volume and Issue


Metabolic effects of sub-chronic ablation of the incretin receptors by daily administration of (Pro3)GIP and exendin(9–39)amide in obese diabetic (ob/ob) mice

Jeremy C. Parker1 / Nigel Irwin2 / Kerry S. Lavery3 / Brian D. Green4 / Finbarr P.M. O'Harte5 / Victor A. Gault6 / Peter R. Flatt7








Corresponding author

Citation Information: Biological Chemistry. Volume 388, Issue 2, Pages 221–226, ISSN (Online) 1437-4315, ISSN (Print) 1431-6730, DOI: https://doi.org/10.1515/BC.2007.024, January 2007

Publication History

August 8, 2006
September 21, 2006
Published Online:


Effects of chemical ablation of the GIP and GLP-1 receptors on metabolic aspects of obesity-diabetes were investigated using the stable receptor antagonists (Pro3)GIP and exendin(9–39)amide. Ob/ob mice received a daily i.p. injection of saline vehicle, (Pro3)GIP, exendin(9–39)amide or a combination of both peptides over a 14-day period. Non-fasting plasma glucose levels were significantly (p<0.05) lower in (Pro3)GIP-treated mice compared to control mice after just 9 days of treatment. (Pro3)GIP-treated mice also displayed significantly lower plasma glucose concentrations in response to feeding and intraperitoneal administration of either glucose or insulin (p<0.05 to p<0.001). The (Pro3)GIP-treated group also exhibited significantly (p<0.05) reduced pancreatic insulin content. Acute administration of exendin(9–39)amide immediately prior to re-feeding completely annulled the beneficial effects of sub-chronic (Pro3)GIP treatment, but non-fasting concentrations of active GLP-1 were unchanged. Combined sub-chronic administration of (Pro3GIP) with exendin(9–39)amide revealed no beneficial effects. Similarly, daily administration of exendin(9–39)amide alone had no significant effects on any of the metabolic parameters measured. These studies highlight an important role for GIP in obesity-related forms of diabetes, suggesting the possible involvement of GLP-1 in the beneficial actions of GIP receptor antagonism.

Keywords: antagonism; exendin(9–39)amide; glucose homeostasis; insulin secretion; ob/ob mice; (Pro3)GIP

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

Robert R. Henry
Current Medical Research and Opinion, 2008, Volume 24, Number 8, Page 2189
N. Mentis, I. Vardarli, L. D. Kothe, J. J. Holst, C. F. Deacon, M. Theodorakis, J. J. Meier, and M. A. Nauck
Diabetes, 2011, Volume 60, Number 4, Page 1270
David Porter, Emilie Faivre, Peter R. Flatt, Christian Hölscher, and Victor A. Gault
Peptides, 2012, Volume 35, Number 1, Page 1
Eamon P. Rafferty, Alastair R. Wylie, Katharine H. Hand, Chris E. Elliott, David J. Grieve, and Brian D. Green
Biological Chemistry, 2011, Volume 392, Number 6
Nigel Irwin and Peter R. Flatt
Best Practice & Research Clinical Endocrinology & Metabolism, 2009, Volume 23, Number 4, Page 499
Ying Sun, Lin Wang, Minghu Jiang, Juxiang Huang, Zhenqiu Liu, and Stefan Wolfl
Cell Biochemistry and Biophysics, 2010, Volume 56, Number 2-3, Page 59

Comments (0)

Please log in or register to comment.